Back

Safety, tolerability and discontinuation causes of sacubitril/valsartan treatment in patients with heart failure and reduced ejection fraction attending to an outpatient heart failure clinic.

25 May 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 3 - Chronic Heart Failure – Treatment Pharmacotherapy HFA Premium Access Heart Failure 2019

About the speaker

Photo
Doctor Marcelo Rizzo

Hospital Universitari Parc Tauli de Sabadell, Sabadell (Spain)

56 More presentations in this session

Presentation thumbnail
Effects of mineralocorticoid ceceptor antagonists (MRA) in heart failure patients after up to 12 months of follow-up.
Doctor L. Borg (Msida, MT)
Abstract
Presentation thumbnail
Sacubitril valsartan, a multicentric experience
Mr F. Cortes (Sevilla, ES)
Abstract
Presentation thumbnail
Reduction of NT-proBNP in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction in short-term treatment with empagliflozin on top of existing therapy
Professor B. Kanazirev (Varna, BG)
Abstract Slides
Presentation thumbnail
Effects of sacubitril/valsartan on real-world patients with heart failure due to non-ischemic cardiomyopathy
Associate Professor C. Hsu (Taipei, TW)
Abstract Slides
Presentation thumbnail
Effects of ivabradine on patients with depressed left ventricular ejection fraction after cardiac resynchronization therapy
Doctor C. Hsieh (Taipei, TW)
Abstract

Access the full session

Session thumbnail
Poster Session 3 - Chronic Heart Failure – Treatment

The Event

Event poster

Heart Failure 2019

25 May - 28 May 2019
You may be interested in
thumbnail
Congress Session
Guideline-directed medical therapy implementation in special clinical scenarios
thumbnail
Congress Presentation
Audience Q&A
thumbnail
Congress Presentation
Did we forget ARNI in the era of SGLTi?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources